We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+9.06%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.6B
AUM Growth
+$2.6B
(+22%)
Cap. Flow
+$859M
Cap. Flow
% of AUM
5.88%
Top 10 Holdings %
Top 10 Hldgs %
21.92%
Holding
958
New
131
Increased
364
Reduced
334
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$135M |
| 2 |
Royal Bank of Canada
RY
|
+$120M |
| 3 |
Agilent Technologies
A
|
+$72.5M |
| 4 |
UnitedHealth
UNH
|
+$71.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$64.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$90.3M |
| 2 |
Amgen
AMGN
|
+$88.7M |
| 3 |
Allstate
ALL
|
+$52.2M |
| 4 |
Union Pacific
UNP
|
+$47.1M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$44.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.42% |
| 2 | Technology | 23.2% |
| 3 | Consumer Discretionary | 9.14% |
| 4 | Financials | 8.63% |
| 5 | Communication Services | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
J.M. Smucker
SJM
$12.9B
| $12.7M | 0.09% |
97,889
+87,044
| +803% | +$11.6M |
|
252
Sportsman's Warehouse
SPWH
$44.9M
| $12.6M | 0.09% |
+709,064
| New | +$12.5M |
|
253
Citizens Financial Group
CFG
$30.1B
| $12.5M | 0.09% |
273,158
+148,440
| +119% | +$7.01M |
|
254
Avantor
AVTR
$8.03B
| $12.5M | 0.09% |
352,662
+131,784
| +60% | +$4.26M |
|
255
Revolution Medicines
RVMD
$40B
| $12.5M | 0.09% |
394,070
+394,060
| +3,940,600% | +$13.8M |
|
256
Labcorp
LH
$24.7B
| $12.5M | 0.09% |
52,549
-192,177
| -79% | -$43.8M |
|
|
KDNY
257
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $12.4M | 0.08% |
+875,124
| New | +$14M |
|
|
CLDR
258
DELISTED
Cloudera, Inc.
CLDR
| $12.3M | 0.08% |
+773,774
| New | +$10.5M |
|
259
Guardant Health
GH
$19.3B
| $12.1M | 0.08% |
97,696
+9,344
| +11% | +$1.26M |
|
|
COHR
260
DELISTED
Coherent Inc
COHR
| $12.1M | 0.08% |
+45,763
| New | +$12M |
|
261
Heron Therapeutics
HRTX
$86.9M
| $11.8M | 0.08% |
758,570
-531,203
| -41% | -$8.45M |
|
262
Edwards Lifesciences
EW
$47.8B
| $11.7M | 0.08% |
112,878
+16,688
| +17% | +$1.57M |
|
|
SWTX
263
DELISTED
SpringWorks Therapeutics
SWTX
| $11.6M | 0.08% |
140,834
+4,955
| +4% | +$376K |
|
264
Moody's
MCO
$84.2B
| $11.6M | 0.08% |
30,667
+1,806
| +6% | +$601K |
|
265
McCormick & Company Non-Voting
MKC
$13.6B
| $11.6M | 0.08% |
131,005
+70,869
| +118% | +$6.32M |
|
266
PTC Therapeutics
PTCT
$6.29B
| $11.6M | 0.08% |
273,374
-326,023
| -54% | -$14M |
|
267
Digital Realty Trust
DLR
$72.4B
| $11.4M | 0.08% |
75,574
+59,947
| +384% | +$9.06M |
|
268
Bunge Global
BG
$22.8B
| $11.3M | 0.08% |
144,082
+126,060
| +699% | +$10.6M |
|
|
NGM
269
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $11.1M | 0.08% |
564,059
+342,425
| +155% | +$8.01M |
|
270
Zentalis Pharmaceuticals
ZNTL
$321M
| $11.1M | 0.08% |
208,526
+208,515
| +1,895,591% | +$11.2M |
|
271
ServiceNow
NOW
$109B
| $10.9M | 0.07% |
99,555
-61,540
| -38% | -$6.24M |
|
272
Electronic Arts
EA
$52.4B
| $10.9M | 0.07% |
75,819
-167,509
| -69% | -$23.8M |
|
273
PagSeguro Digital
PAGS
$2.62B
| $10.7M | 0.07% |
191,750
-43,200
| -18% | -$2.08M |
|
274
Deere & Co
DE
$169B
| $10.7M | 0.07% |
30,261
-22,439
| -43% | -$8.19M |
|
275
Wells Fargo
WFC
$264B
| $10.6M | 0.07% |
234,246
+6,657
| +3% | +$297K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2021 Portfolio in Review
As of Q2 2021, Candriam SCA held 958 positions worth $14.6B, up 22% from $12B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Candriam SCA deployed $859M of net new capital in Q2 2021, opening 131 new positions and adding to 364 existing holdings. Its largest new stake was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $90.3M trimmed.
- Candriam SCA's largest Q2 2021 buy was SailPoint Technologies Holdings, Inc. Common Stock: 738,233 shares worth $37.7M.
- Candriam SCA added most to Microsoft in Q2 2021, an estimated $135M increase.
- Candriam SCA's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $90.3M.
- Candriam SCA fully exited Tenable Holdings in Q2 2021, selling an estimated $31.6M.
- Candriam SCA's ten largest holdings make up 22% of its $14.6B portfolio in Q2 2021.
- Candriam SCA opened 131 new positions and closed 74 in Q2 2021.
- Candriam SCA's portfolio value rose 22% quarter-over-quarter to $14.6B.
Based on Candriam SCA's 13F filing for Q2 2021, filed 20 Jul 2021.